• 1
    Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010; 28: 586-595.
  • 2
    Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361: 1249-1259.
  • 3
    Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009; 27: 5397-5403.
  • 4
    Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99: 252-257.
  • 5
    Wetzler M, Brady MT, Tracy E, et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006; 12: 6817-6825.
  • 6
    Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004; 28: 909-919.
  • 7
    Baer MR, Pixley LA, Ford L, et al. High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (pts) <60 years old [abstract]. Blood. 2000; 96: 322a.
  • 8
    Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24: 2465-2471.
  • 9
    Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett. 2000; 112/113: 209-217.
  • 10
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649.
  • 11
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 12
    Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 3342-3347.
  • 13
    Marnell LL, Garcia-Vargas GG, Chowdhury UK, et al. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol. 2003; 16: 1507-1513.
  • 14
    Agusa T, Iwata H, Fujihara J, et al. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol Appl Pharmacol. 2009; 236: 131-141.
  • 15
    Chung CJ, Hsueh YM, Bai CH, et al. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Control. 2009; 20: 1653-1661.
  • 16
    Porter KE, Basu A, Hubbard AE, et al. Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010; 110: 580-587.
  • 17
    Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354-3360.
  • 18
    Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity—pharmacodynamic drug-drug interaction modeling. Clin Cancer Res. 2007; 13: 2261-2270.
  • 19
    Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol. 2010; 66: 681-689.
  • 20
    Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009; 27: 4422-4432.
  • 21
    Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008; 453: 1072-1078.
  • 22
    Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14: 1333-1342.